Pacira BioSciences
PCRX
187 hedge funds and large institutions have $2.01B invested in Pacira BioSciences in 2018 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 53 increasing their positions, 59 reducing their positions, and 15 closing their positions.
207% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 15
47% more capital invested
Capital invested by funds: $1.37B → $2.01B (+$641M)
20% more funds holding
Funds holding: 156 → 187 (+31)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less call options, than puts
Call options by funds: $42.5M | Put options by funds: $44.4M
5.48% less ownership
Funds ownership: 105.3% → 99.83% (-5.5%)
10% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$16.9M |
| 2 |
Millennium Management
New York
|
+$16.3M |
| 3 |
Goldman Sachs
New York
|
+$15.5M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$12.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$59.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$45.3M |
| 3 |
HM
HealthCor Management
New York
|
-$39.3M |
| 4 |
DCM
Daruma Capital Management
New York
|
-$29.1M |
| 5 |
ECP
Elk Creek Partners
Denver,
Colorado
|
-$27.8M |
PCRX Hedge Fund Activity: Q3 2018 in Review
187 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2018, worth a combined $2.01B — up 47% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new PCRX positions and 15 closed out — a net gain of 31 holders — while 53 added to existing stakes and 59 trimmed.
The largest buyer was Invesco, adding an estimated $16.9M. The largest seller was PointState Capital, cutting an estimated $59.1M.
- 187 institutional investors held Pacira BioSciences (PCRX) as of Q3 2018, up from 156 in Q2 2018.
- Funds reported $2.01B of Pacira BioSciences stock for Q3 2018, up 47% quarter-over-quarter.
- 46 funds opened new Pacira BioSciences positions in Q3 2018 and 15 closed out, a net change of +31 holders.
- The largest Pacira BioSciences buyer in Q3 2018 was Invesco, an estimated $16.9M added.
- The largest Pacira BioSciences seller in Q3 2018 was PointState Capital, an estimated $59.1M sold.
Based on aggregated 13F filings for Q3 2018.